Jump to content

Tavilermide: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Monkbot (talk | contribs)
Bots
3,695,952 edits
m Task 18 (cosmetic): eval 7 templates: del empty params (3×);
Monkbot (talk | contribs)
Bots
3,695,952 edits
m Task 18 (cosmetic): eval 7 templates: hyphenate params (1×);
Line 49: Line 49:
}}
}}


'''Tavilermide''' ([[International Nonproprietary Name|INN]]) (developmental code name '''MIM-D3''') is a [[binding selectivity|selective]], [[cyclic peptide]] [[partial agonist]] of [[TrkA]]. (this class of drugs are sometimes known as [[nerve growth factor]] (NGF) [[mimetic]]s)<ref name="MeerovitchTorkildsen2013">{{cite journal|last1=Meerovitch|first1=Karen|last2=Torkildsen|first2=Gail|last3=Lonsdale|first3=John|last4=Goldfarb|first4=Heidi|last5=Lama|first5=Teresa|last6=Cumberlidge|first6=Garth|last7=Ousler III|first7=George W.|title=Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye|journal=Clinical Ophthalmology|volume=7|year=2013|pages=1275–85|issn=1177-5483|doi=10.2147/OPTH.S44688|pmid=23836957|pmc=3699314}}</ref><ref name="JainLi2011">{{cite journal|last1=Jain|first1=Pooja|last2=Li|first2=Ruihong|last3=Lama|first3=Teresa|last4=Saragovi|first4=H. Uri|last5=Cumberlidge|first5=Garth|last6=Meerovitch|first6=Karen|title=An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye|journal=Experimental Eye Research|volume=93|issue=4|year=2011|pages=503–512|issn=0014-4835|doi=10.1016/j.exer.2011.06.014|pmid=21726552}}</ref><ref name="VickersGupta2015">{{cite journal|last1=Vickers|first1=Laura A.|last2=Gupta|first2=Preeya K.|title=The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline|journal=Ophthalmology and Therapy|volume=4|issue=2|pages=69–78|year=2015|issn=2193-8245|doi=10.1007/s40123-015-0038-y|pmid=26289997|pmc=4675732}}</ref> Tavilermide was first synthesized by Burgess and co-workers at Texas A&M University with the intention of producing TrkA agonists.<ref>{{Cite journal|last=Feng|first=Yangbo|last2=Wang|first2=Zhicheng|last3=Jin|first3=Song|last4=Burgess|first4=Kevin|date=1998|title=S<sub>N</sub>Ar Cyclizations To Form Cyclic Peptidomimetics of β-Turns|url=https://pubs.acs.org/doi/10.1021/ja981589t|journal=Journal of the American Chemical Society|volume=120|pages=10768-10769|doi=10.1021/ja981589t}}</ref><ref>{{Cite journal|last=Feng|first=Yangbo|last2=Burgess|first2=Kevin|date=1999|title=Solid-phase S<sub>N</sub>Ar macrocyclizations to give turn-extended-turn peptidomimetics|url=https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291521-3765%2819991105%295%3A11%3C3261%3A%3AAID-CHEM3261%3E3.0.CO%3B2-H|journal=Chemistry—A European Journal|volume=5|pages=3261-3272|doi=10.1002/(SICI)1521-3765(19991105)5:11<3261::AID-CHEM3261>3.0.CO;2-H}}</ref> It is under development by Mimetogen Pharmaceuticals as an [[ophthalmic solution|ophthalmic (eye drop) solution]] for the treatment of [[dry eyes]], and is in [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for this indication. Tavilermide is currently being evaluated in two multi-center phase III clinical studies in the United States for the treatment of dry eye disease.[http://www.streetinsider.com/Corporate+News/Allergan+%28AGN%29,+Mimetogen+Pharma+Enter+MIM-D3+D+Development+Collaboration/11033405.html] Tavilermide is also in [[Phases of clinical research#Phase I|phase I]] clinical trials for the treatment of [[glaucoma]]; studies are ongoing.<ref name="pmid22349567">{{cite journal | vauthors = Chang EE, Goldberg JL | title = Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement | journal = Ophthalmology | volume = 119 | issue = 5 | pages = 979–86 | year = 2012 | pmid = 22349567 | pmc = 3343191 | doi = 10.1016/j.ophtha.2011.11.003 }}</ref><ref>{{cite web|title=Tavilermide - AdisInsight|url=http://adisinsight.springer.com/drugs/800033231|publisher=adisinsight.springer.com|accessdate=18 August 2016}}</ref>
'''Tavilermide''' ([[International Nonproprietary Name|INN]]) (developmental code name '''MIM-D3''') is a [[binding selectivity|selective]], [[cyclic peptide]] [[partial agonist]] of [[TrkA]]. (this class of drugs are sometimes known as [[nerve growth factor]] (NGF) [[mimetic]]s)<ref name="MeerovitchTorkildsen2013">{{cite journal|last1=Meerovitch|first1=Karen|last2=Torkildsen|first2=Gail|last3=Lonsdale|first3=John|last4=Goldfarb|first4=Heidi|last5=Lama|first5=Teresa|last6=Cumberlidge|first6=Garth|last7=Ousler III|first7=George W.|title=Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye|journal=Clinical Ophthalmology|volume=7|year=2013|pages=1275–85|issn=1177-5483|doi=10.2147/OPTH.S44688|pmid=23836957|pmc=3699314}}</ref><ref name="JainLi2011">{{cite journal|last1=Jain|first1=Pooja|last2=Li|first2=Ruihong|last3=Lama|first3=Teresa|last4=Saragovi|first4=H. Uri|last5=Cumberlidge|first5=Garth|last6=Meerovitch|first6=Karen|title=An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye|journal=Experimental Eye Research|volume=93|issue=4|year=2011|pages=503–512|issn=0014-4835|doi=10.1016/j.exer.2011.06.014|pmid=21726552}}</ref><ref name="VickersGupta2015">{{cite journal|last1=Vickers|first1=Laura A.|last2=Gupta|first2=Preeya K.|title=The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline|journal=Ophthalmology and Therapy|volume=4|issue=2|pages=69–78|year=2015|issn=2193-8245|doi=10.1007/s40123-015-0038-y|pmid=26289997|pmc=4675732}}</ref> Tavilermide was first synthesized by Burgess and co-workers at Texas A&M University with the intention of producing TrkA agonists.<ref>{{Cite journal|last=Feng|first=Yangbo|last2=Wang|first2=Zhicheng|last3=Jin|first3=Song|last4=Burgess|first4=Kevin|date=1998|title=S<sub>N</sub>Ar Cyclizations To Form Cyclic Peptidomimetics of β-Turns|url=https://pubs.acs.org/doi/10.1021/ja981589t|journal=Journal of the American Chemical Society|volume=120|pages=10768-10769|doi=10.1021/ja981589t}}</ref><ref>{{Cite journal|last=Feng|first=Yangbo|last2=Burgess|first2=Kevin|date=1999|title=Solid-phase S<sub>N</sub>Ar macrocyclizations to give turn-extended-turn peptidomimetics|url=https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/%28SICI%291521-3765%2819991105%295%3A11%3C3261%3A%3AAID-CHEM3261%3E3.0.CO%3B2-H|journal=Chemistry—A European Journal|volume=5|pages=3261-3272|doi=10.1002/(SICI)1521-3765(19991105)5:11<3261::AID-CHEM3261>3.0.CO;2-H}}</ref> It is under development by Mimetogen Pharmaceuticals as an [[ophthalmic solution|ophthalmic (eye drop) solution]] for the treatment of [[dry eyes]], and is in [[Phases of clinical research#Phase III|phase III]] [[clinical trial]]s for this indication. Tavilermide is currently being evaluated in two multi-center phase III clinical studies in the United States for the treatment of dry eye disease.[http://www.streetinsider.com/Corporate+News/Allergan+%28AGN%29,+Mimetogen+Pharma+Enter+MIM-D3+D+Development+Collaboration/11033405.html] Tavilermide is also in [[Phases of clinical research#Phase I|phase I]] clinical trials for the treatment of [[glaucoma]]; studies are ongoing.<ref name="pmid22349567">{{cite journal | vauthors = Chang EE, Goldberg JL | title = Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement | journal = Ophthalmology | volume = 119 | issue = 5 | pages = 979–86 | year = 2012 | pmid = 22349567 | pmc = 3343191 | doi = 10.1016/j.ophtha.2011.11.003 }}</ref><ref>{{cite web|title=Tavilermide - AdisInsight|url=http://adisinsight.springer.com/drugs/800033231|publisher=adisinsight.springer.com|access-date=18 August 2016}}</ref>


==See also==
==See also==

Revision as of 23:53, 19 January 2021

Tavilermide
Clinical data
Routes of
administration		Eye drop
ATC code
  • None
Identifiers
  • 3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H32N6O11
Molar mass580.551 g·mol−1
3D model (JSmol)
  • C1COC2=C(C=C(C=C2)[N+](=O)[O-])C(=O)NC(C(=O)NC(C(=O)NC1C(=O)NCC(=O)O)CCCCN)CCC(=O)O
  • InChI=1S/C24H32N6O11/c25-9-2-1-3-15-23(37)29-17(22(36)26-12-20(33)34)8-10-41-18-6-4-13(30(39)40)11-14(18)21(35)27-16(24(38)28-15)5-7-19(31)32/h4,6,11,15-17H,1-3,5,7-10,12,25H2,(H,26,36)(H,27,35)(H,28,38)(H,29,37)(H,31,32)(H,33,34)/t15-,16-,17-/m0/s1
  • Key:DVJXNXPFYJIACK-ULQDDVLXSA-N

Tavilermide (INN) (developmental code name MIM-D3) is a selective, cyclic peptide partial agonist of TrkA. (this class of drugs are sometimes known as nerve growth factor (NGF) mimetics)[1][2][3] Tavilermide was first synthesized by Burgess and co-workers at Texas A&M University with the intention of producing TrkA agonists.[4][5] It is under development by Mimetogen Pharmaceuticals as an ophthalmic (eye drop) solution for the treatment of dry eyes, and is in phase III clinical trials for this indication. Tavilermide is currently being evaluated in two multi-center phase III clinical studies in the United States for the treatment of dry eye disease.[1] Tavilermide is also in phase I clinical trials for the treatment of glaucoma; studies are ongoing.[6][7]

See also

References

  1. ^ Meerovitch, Karen; Torkildsen, Gail; Lonsdale, John; Goldfarb, Heidi; Lama, Teresa; Cumberlidge, Garth; Ousler III, George W. (2013). "Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye". Clinical Ophthalmology. 7: 1275–85. doi:10.2147/OPTH.S44688. ISSN 1177-5483. PMC 3699314. PMID 23836957.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  2. ^ Jain, Pooja; Li, Ruihong; Lama, Teresa; Saragovi, H. Uri; Cumberlidge, Garth; Meerovitch, Karen (2011). "An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye". Experimental Eye Research. 93 (4): 503–512. doi:10.1016/j.exer.2011.06.014. ISSN 0014-4835. PMID 21726552.
  3. ^ Vickers, Laura A.; Gupta, Preeya K. (2015). "The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline". Ophthalmology and Therapy. 4 (2): 69–78. doi:10.1007/s40123-015-0038-y. ISSN 2193-8245. PMC 4675732. PMID 26289997.
  4. ^ Feng, Yangbo; Wang, Zhicheng; Jin, Song; Burgess, Kevin (1998). "SNAr Cyclizations To Form Cyclic Peptidomimetics of β-Turns". Journal of the American Chemical Society. 120: 10768–10769. doi:10.1021/ja981589t.
  5. ^ Feng, Yangbo; Burgess, Kevin (1999). "Solid-phase SNAr macrocyclizations to give turn-extended-turn peptidomimetics". Chemistry—A European Journal. 5: 3261–3272. doi:10.1002/(SICI)1521-3765(19991105)5:11<3261::AID-CHEM3261>3.0.CO;2-H.
  6. ^ Chang EE, Goldberg JL (2012). "Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement". Ophthalmology. 119 (5): 979–86. doi:10.1016/j.ophtha.2011.11.003. PMC 3343191. PMID 22349567.
  7. ^ "Tavilermide - AdisInsight". adisinsight.springer.com. Retrieved 18 August 2016.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Tavilermide&oldid=1001500036"